Hopp til hovedinnhold


Sist oppdatert: Sist revidert:
Sist revidert av:



  1. https://www.kreftregisteret.no/globalassets/cancer-in-norway/2018/cin2018.pdf
  2. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014 Jul;16(7):896-913. doi: 10.1093/neuonc/nou087 DOI  
  3. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.PMID: 27157931 PubMed  
  4. Pajtler KW, Witt H, Sill M, et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 2015;27(5):728-743. doi:10.1016/j.ccell.2015.04.002 DOI  
  5. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma.Nat Rev Neurol. 2019 Jul;15(7):405-417. doi: 10.1038/s41582-019-0220-2. Epub 2019 Jun 21.PMID: 31227792 PubMed  
  6. Louis DN, Aldape K, Brat DJ, et al. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2017;27(6):851-852. doi:10.1111/bpa.12457 DOI  
  7. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017 Jul;14(7):434-452. doi: 10.1038/nrclinonc.2016.204. Epub 2016 Dec 29.PMID: 28031556 PubMed  
  8. Chen DY, Chen CC, Crawford JR, Wang SG. Tumor-related epilepsy: epidemiology, pathogenesis and management. J Neurooncol. 2018 Aug;139(1):13-21. doi: 10.1007/s11060-018-2862-0. Epub 2018 May 24.PMID: 29797181 PubMed  
  9. Taylor LP. Mechanism of brain tumor headache. Headache. 2014 Apr;54(4):772-5. doi: 10.1111/head.12317. Epub 2014 Mar 13.PMID: 24628259 PubMed  
  10. Larsen J, Hoggard N, McKevitt FM. Imaging in low-grade glioma: a guide for neurologists. Pract Neurol. 2018 Feb;18(1):27-34. doi: 10.1136/practneurol-2017-001686. Epub 2017 Dec 5. Review. PMID: 29208728 PubMed  
  11. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5.PMID: 28483413 PubMed  
  12. Ma R, Taphoorn MJB, Plaha P. Advances in the management of glioblastoma. J Neurol Neurosurg Psychiatry. 2021 Oct;92(10):1103-1111. doi: 10.1136/jnnp-2020-325334. Epub 2021 Jun 23. PMID: 34162730. PubMed  
  13. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, Solheim O. Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas. JAMA 2012: 1-8. doi: 10.1001/jama.2012.12807. PMID:24043414 PubMed
  14. Jakola AS, Skjulsvik AJ, Myrmel KS, Sjåvik K, Unsgård G, Torp SH, Aaberg K, Berg T, Dai HY, Johnsen K, Kloster R, Solheim O. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017 Aug 1;28(8):1942-1948. doi: 10.1093/annonc/mdx230.PMID: 28475680 PubMed  
  15. Hayhurst C. Contemporary management of low--grade glioma: a paradigm shift in neuro-oncology. Pract Neurol. 2017 Jun;17(3):183-190. doi: 10.1136/practneurol-2017-001604. Epub 2017 Mar 18. Review. . pmid:28315827 PubMed  
  16. Antonsson M, Jakola A, Longoni F, Carstam L, Hartelius L, Thordstein M, Tisell M. Post-surgical effects on language in patients with presumed low-grade glioma. Acta Neurol Scand. 2017 Dec 18. doi: 10.1111/ane.12887. Epub ahead of print PMID: 29265169 PubMed  
  17. Duran-Peña A, Ducray F, Ramirez C, Bauchet L, Constans JM, Grand S, Guillamo JS, Larrieu-Ciron D, Frappaz D, Pyatigorskaya N, Savatovsky J, Loiseau H, Duverneuil NM, Laigle-Donadey F. Adult brainstem glioma differential diagnoses: an MRI-based approach in a series of 68 patients. J Neurol. 2022 Aug;269(8):4349-4362. doi: 10.1007/s00415-022-11070-6. Epub 2022 Apr 20. PMID: 35441889. PubMed  
  18. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ Jr. V. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016 Apr 7;374(14):1344-55. doi: 10.1056/NEJMoa1500925.PMID: 27050206 PubMed  
  19. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB; EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-gradeastrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005 Sep 17-23;366(9490):985-90. doi: 10.1016/S0140-6736(05)67070-5.PMID: 16168780 PubMed  
  20. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, Darcel F, Stenning S, Pierart M, Van Glabbeke M.. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.. Int J Radiat Oncol Biol Phys. 2002; 52(2): 316-24. pmid:11872276 PubMed  
  21. van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017 Aug 8. pii: S0140-6736(17)31442-3 . pmid:28801186 PubMed  
  22. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1.PMID: 25934816 PubMed  
  23. Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018 Jul;15(7):422-442. doi: 10.1038/s41571-018-0003-5.PMID: 29643471 PubMed  
  24. Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Burna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. PMID: 29260225 PubMed  
  25. Bedetti C, Romoli M, Maschio M, Di Bonaventura C, Nardi Cesarini E, Eusebi P, Siliquini S, Dispenza S, Calabresi P, Costa C. Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study. Eur J Neurol. 2017 Oct;24(10):1283-1289 . pmid:28796376 PubMed  
  26. Yuan Y, Xiang W, Qing M, Yanhui L, Jiewen L, Yunhe M. Survival analysis for valproic acid use in adult glioblastoma multiforme: A meta-analysis of individual patient data and a systematic review. Seizure 2014. pmid:25066904 PubMed  
  27. Knudsen-Baas KM, Engeland A, Gilhus NE, Storstein AM, Owe JF. Does the choice of antiepileptic drug affect survival in glioblastoma patients? J Neurooncol. 2016 Sep;129(3):461-469. doi: 10.1007/s11060-016-2191-0. Epub 2016 Jul 4.PMID: 27377653 PubMed  
  28. Kerkhof M, Koekkoek JAF, Vos MJ, van den Bent MJ, Taal W, Postma TJ, Bromberg JEC, Kouwenhoven MCM, Dirven L, Reijneveld JC, Taphoorn MJB. Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study. J Neurooncol. 2019 May;142(3):463-470 PubMed  
  29. Kourilsky A, Bertrand G, Ursu R, Doridam J, Barlog C, Faillot T, Mandonnet E, Belin C, Levy C, Carpentier AF. Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients. J Neurol. 2016 Mar;263(3):524-30 . pmid:26754004 PubMed  
  30. Eisele A, Seystahl K, Rushing EJ, Roth P, Le Rhun E, Weller M, Gramatzki D. Venous thromboembolic events in glioblastoma patients: An epidemiological study. Eur J Neurol. 2022 Aug;29(8):2386-2397. doi: 10.1111/ene.15404. Epub 2022 May 31. PMID: 35545894 PubMed  
  31. Dirven L, Sizoo EM, Taphoorn MJ. Anaplastic gliomas: end-of-life care recommendations. CNS Oncol. 2015 Oct;4(5):357-65 . pmid:26509292 PubMed  
  32. Wann A, Tully PA, Barnes EH, Lwin Z, Jeffree R, Drummond KJ, Gan H, Khasraw M. Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study. J Neurooncol. 2018 Apr;137(2):409-415. doi: 10.1007/s11060-017-2731-2. Epub 2018 Jan 2.PMID: 29294233 PubMed  
  33. Zwirner K, Paulsen F, Schittenhelm J, Borchers C, Skardelly M, Zips D, Eckert F. Prognostic parameters and outcome after re-irradiation for progressive glioblastoma. Acta Neurol Scand. 2017 Sep;136(3):239-245 . pmid:28025828 PubMed  
  34. Niranjan A, Faramand A, Lunsford LD. Stereotactic Radiosurgery for Low-Grade Gliomas. Prog Neurol Surg. 2019;34:184-190. doi: 10.1159/000493063. Epub 2019 May 16.PMID: 31096253 PubMed  
  35. Niranjan A, Kano H, Monaco Iii EA, Lunsford LD. Salvage Leksell Stereotactic Radiosurgery for Malignant Gliomas. Prog Neurol Surg. 2019;34:191-199. doi: 10.1159/000493064. Epub 2019 May 16.PMID: 31096255 PubMed  
  36. Hottinger AF, Homicsko K, Negretti L, Lhermitte B, Stupp R. Decision making and management of gliomas: practical considerations. Ann Oncol 2012; 23 Suppl 10:x33-40. PMID:22987986 PubMed  
  37. Pace A, Vidiri A, GalièE, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003;14(12):1722.
  38. Seystahl K, Wick W, Weller M. Therapeutic options in recurrent glioblastoma--An update. Crit Rev Oncol Hematol. 2016 Mar;99:389-408. doi: 10.1016/j.critrevonc.2016.01.018. Epub 2016 Jan 21.PMID: 26830009 PubMed  
  39. Parasramka S, Talari G, Rosenfeld M, Guo J, Villano JL. Procarbazine, lomustine and vincristine for recurrent high-grade glioma. Cochrane Database Syst Rev. 2017 Jul 26;7:CD011773 . pmid:28744879 PubMed  
  40. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358. PMID: 29141164 PubMed  
  41. Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev 2014. pmid:25242542 PubMed  
  42. Schiff D, Van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, Pope W, Brown PD, Platten M, Jalali R, Armstrong T, Wen PY. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro Oncol. 2019 Jul 11;21(7):837-853. doi: 10.1093/neuonc/noz033.PMID: 30753579 PubMed  
  43. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG).. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012 ; 9: 916-26. pmid: 22877848 PubMed  
  44. Rusthoven CG, Koshy M, Sher DJ, Ney DE, Gaspar LE, Jones BL, Karam SD, Amini A, Ormond DR, Youssef AS, Kavanagh BD. Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis. JAMA Neurol. 2016 Jul 1;73(7):821-8 . pmid:27214765 PubMed  
  45. Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017 Sep;134(3):495-504. doi: 10.1007/s11060-017-2375-2. Epub 2017 Apr 5.PMID: 28382534 PubMed  
  46. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET,Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963.PMID: 20231676 PubMed  
  47. Di Stefano AL, Berzero G, Vitali P, Galimberti CA, Ducray F, Ceroni M, Bastianello S, Colombo AA, Simoncelli A, Brunelli MC, Giometto B, Diamanti L, Gaviani P, Salmaggi A, Silvani A, Marchioni E. Acute late-onset encephalopathy after radiotherapy: an unusual life-threatening complication. Neurology 2013; 81: 1014-7. pmid:23935180 PubMed  
  48. Jia W, Saito R, Kanamori M, Iwabuchi N, Iwasaki M, Tominaga T. SMART (stroke-like migraine attacks after radiation therapy) syndromeresponded to steroid pulse therapy: Report of a case and review of the literature. eNeurologicalSci. 2018 May 23;12:1-4. doi: 10.1016/j.ensci.2018.05.003. eCollection 2018 Sep.PMID: 30003148 PubMed  
  49. Fekete B, Werlenius K, Örndal C, Rydenhag B. Prognostic factors for glioblastoma patients - a clinical population-based study. Acta Neurol Scand. 2015. pmid: 26358197 PubMed  
  50. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB; European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002 Apr 15;20(8):2076-84. doi: 10.1200/JCO.2002.08.121.PMID: 11956268 PubMed  
  • Anette Storstein, spesialist i nevrologi, dr med
  • Petter Brandal, spesialist i onkologi, PhD
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevrologi, professor dr med